Aesthetic Outcome of Tie-over Bolster Application in Surgical Wounds

Sponsor
University of California, Davis (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05758168
Collaborator
(none)
50
2
2
15
25
1.7

Study Details

Study Description

Brief Summary

When patients have surgery on the head and face, stitches are the standard way to close the wound. Wounds always result in a scar, but doctors are always looking for ways to reduce scarring. Several studies have been done to test ways to close wounds that reduce scarring. One idea is to reduce the tension around the cut. One way to reduce tension is to stitch a small piece of a special gauze over the top of the regular stitches. This procedure is called a "tie-over bolster dressing." As the name implies, this extra dressing "bolsters" the wound closure so that the skin on each side of the cut stays in place.

The bolster dressing procedure has been used in the past in special cases, such as when skin grafts are necessary. The bolster dressing helps the skin graft heal by making sure the graft stays exactly in place. Keeping the wound stable with a bolster dressing also reduces bleeding under the wound. For non-grafted wounds, the bolster dressing procedure has not normally been used, and has not been well-studied. In this study the whole wound will be stitched normally and then the bolster dressing will be applied over half of the wound. This will allow us to see if the side with the bolster dressing heals with less scarring.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Addition of Tie-Over Bolster Dressing
N/A

Detailed Description

Following cutaneous surgical procedures, scar formation is inevitable. Reducing the degree of scar formation and achieving the best aesthetic outcome remains prominent within the dermatological literature. Recent research has highlighted the impact of mechanical forces and tension on scar formation, demonstrating that reducing the mechanical stress within the wound environment results in better aesthetic outcome (1,2). Tension-shielding devices have shown promise in scar reduction in both humans and porcine models (2). More recently, two clinical trials have shown that the use of an "embrace" device, a silicone-based dressing designed to minimize wound tension, effectively improves the aesthetic outcome following scar revision surgery (3,4). In addition, application of negative pressure via vacuum sealing drainage (VSD), commonly called a "wound-vac", has been consistently shown to accelerate wound healing (5). However, using these methods can be challenging, particularly due to cost, practicability, and patient compliance.

An alternative method for reducing mechanical stressors along scars has long been used within dermatologic surgery, namely the application of a bolster dressing.

For decades, tie-over bolster dressings have been employed following cutaneous procedures repaired with skin grafting. Typically, these bolsters are composed of Xeroform gauze (bismuth tribromophenate petrolatum-impregnated gauze) which are sutured on top of the graft. These have been shown to stabilize the graft, immobilize the wound bed, and reduce hematoma formation by delivering persistent downward pressure (6,7).

To our knowledge, the impact of scar cosmesis and rate of post-operative complications following the administration of tie-over bolster dressing over primary linear repair of surgical wounds have not been studied. This study seeks to determine the effectiveness of a tie-over bolster dressing in reducing tension to improve scar cosmesis by using individuals as their own controls in a split-scar model.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Masking:
Single (Outcomes Assessor)
Masking Description:
Two blinded observers will record their scores independently using the POSAS instrument.
Primary Purpose:
Other
Official Title:
Aesthetic Outcome of Tie-over Bolster Application in Surgical Wounds: a Randomized Evaluator-blinded Split-wound Comparative Effectiveness Trial.
Anticipated Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
Aug 1, 2024
Anticipated Study Completion Date :
Aug 1, 2024

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Layered Closure

A cutaneous layer of sutures will be placed on one side of wound, as is standard of care.

Experimental: Layered Closure with Tie-Over Bolster Dressing

The other side of wound will have a cutaneous layer of sutures with the addition of a bolster dressing.

Procedure: Addition of Tie-Over Bolster Dressing
Bolster will be sutured into place using peripheral non-absorbable anchoring sutures.

Outcome Measures

Primary Outcome Measures

  1. Observer Scar Assessment as measured by Patient Observer Scar Assessment Score (POSAS) [3 months]

    The primary endpoint will be the score of two blinded reviewers independently using the POSAS assessment. The observer scale of the POSAS consists of six items (vascularity, pigmentation, thickness, relief, pliability, and surface area). All items are scored on a scale ranging from 1 ("like normal skin") to 10 ("worst scar imaginable"). The sum of the six items results in a total score of the POSAS observer scale. Furthermore, an overall opinion is scored on a scale ranging from 1 to 10. All parameters should preferably be compared to normal skin on a comparable anatomic location.

Secondary Outcome Measures

  1. Patient Scar Assessment as measured by Patient Observer Scar Assessment Score (POSAS) [3 months]

    This is the patient portion of the POSAS assessment, which will be independently recorded. The patient scale of the POSAS consists of six items (pain, itch, thickness, color, stiffness, and irregularity). All items are scored on a scale ranging from 1 ("as normal skin") to 10 ("yes, very different"). The sum of the six items results in a total score of the POSAS patient scale. Furthermore, an overall opinion is scored on a scale ranging from 1 to 10.

  2. Width of Scar as measured using Trace-to-Tape Method [3 months]

    The trace-to-tape method is an objective measure for linear postoperative scars. The mean scar width will be determined using the trace-to-tape method. The surface area of the scar will be collected by tracing the scar with a water-based gel pen. While still wet, the gel residue will be lifted from the skin with clear packing tape and transferred on a sheet of paper.

  3. Complications or Adverse Events from Treatment [3 months]

    For example, if one half of the scar has more associated erythema, as measured using the Trace-to-Tape method, then it will be recorded. Other complications from the treatment will also be recorded.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18 years of age or older

  • Able to give informed consent themselves

  • Patient scheduled for cutaneous surgical procedure on the head or neck with predicted primary closure

  • Willing to return for follow-up visit

Exclusion Criteria:
  • Incarceration

  • Under 18 years of age

  • Pregnant women

  • Unable to understand written and oral English Wounds with predicted closure length less than 3cm

Contacts and Locations

Locations

Site City State Country Postal Code
1 UC Davis Dermatology Sacramento California United States 95816
2 University of California, Davis - Dermatology Department Sacramento California United States 95816

Sponsors and Collaborators

  • University of California, Davis

Investigators

  • Principal Investigator: Daniel Eisen, MD, University of California, Davis - Dermatology

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Daniel Eisen, MD, Professor of Clinical Dermatology, Director of Dermatologic Surgery, University of California, Davis
ClinicalTrials.gov Identifier:
NCT05758168
Other Study ID Numbers:
  • 1977459
First Posted:
Mar 7, 2023
Last Update Posted:
Mar 9, 2023
Last Verified:
Mar 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Daniel Eisen, MD, Professor of Clinical Dermatology, Director of Dermatologic Surgery, University of California, Davis
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 9, 2023